Clinical tests reported the tumour to be MSS and Epstein Barr negative and to not carry any mutations in the POLE gene, thus meaning carrying all the biomarkers that so far have been identified as negative predictors of response to immunotherapy. This evidence concerns the gene POLE and neoplasm.